These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34336262)

  • 1. Efficacy and Safety of Different Intravenous Glucocorticoid Regimens in the Treatment of Graves' Ophthalmopathy: A Meta-Analysis.
    Chen J; Xu N; Sun H; Chen G
    J Ophthalmol; 2021; 2021():9799274. PubMed ID: 34336262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies for the treatment of Graves' ophthalmopathy: A systematic review and meta-analysis.
    Fatani WA; Hamdan DM; Taher NO; Alsharef JF; Aldubi RM; Alwagdani AM; Alhothali TN; Khan ZU
    Saudi J Ophthalmol; 2023; 37(2):137-148. PubMed ID: 37492211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network Meta-Analysis of Different Intravenous Glucocorticoid Regimes for the Treatment of Graves' Orbitopathy.
    Jia J; Dong J; Deng L
    Front Pharmacol; 2022; 13():785757. PubMed ID: 35559245
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials.
    Shen WC; Lee CH; Loh EW; Hsieh AT; Chen L; Tam KW
    Pharmacotherapy; 2018 May; 38(5):503-510. PubMed ID: 29601105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticoid regimens for prevention of Graves' ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis.
    Shiber S; Stiebel-Kalish H; Shimon I; Grossman A; Robenshtok E
    Thyroid; 2014 Oct; 24(10):1515-23. PubMed ID: 25068172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis.
    Chen J; Chen G; Sun H
    Hormones (Athens); 2021 Jun; 20(2):279-286. PubMed ID: 33783712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common Immunosuppressive Monotherapy for Graves' Ophthalmopathy: A Meta-Analysis.
    Mou P; Jiang LH; Zhang Y; Li YZ; Lou H; Zeng CC; Wang QH; Cheng JW; Wei RL
    PLoS One; 2015; 10(10):e0139544. PubMed ID: 26469187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic safety analysis of mycophenolate in Graves' orbitopathy.
    Lee ACH; Riedl M; Frommer L; Diana T; Kahaly GJ
    J Endocrinol Invest; 2020 Jun; 43(6):767-777. PubMed ID: 31834613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mycophenolate mofetil in the treatment of moderate to severe Graves' orbitopathy: a meta-analysis.
    Feng W; Hu Y; Zhang C; Shi H; Zhang P; Yang Y; Chen S; Cui W; Cui D
    Bioengineered; 2022 Jun; 13(6):14719-14729. PubMed ID: 35959915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
    Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
    Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone: a comparison of two dosing regimens.
    Sánchez-Ortiga R; Moreno-Pérez O; González Sánchez V; Arias Mendoza N; Mauri Dot M; Alfayate Guerra R; López Macia A; Picó Alfonso A
    Endocrinol Nutr; 2009 Mar; 56(3):118-22. PubMed ID: 19627724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients.
    Sánchez-Bilbao L; Martínez-López D; Revenga M; López-Vázquez Á; Valls-Pascual E; Atienza-Mateo B; Valls-Espinosa B; Maiz-Alonso O; Blanco A; Torre-Salaberri I; Rodríguez-Méndez V; García-Aparicio Á; Veroz-González R; Jovaní V; Peiteado D; Sánchez-Orgaz M; Tomero E; Toyos-Sáenz de Miera FJ; Pinillos V; Aurrecoechea E; Mora Á; Conesa A; Fernández-Prada M; Troyano JA; Calvo-Río V; Demetrio-Pablo R; González-Mazón Í; Hernández JL; Castañeda S; González-Gay MÁ; Blanco R
    J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32878150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients.
    Villagelin D; Romaldini J; Andrade J; Santos R; Milkos A; Teixeira PFDS; Ward LS
    Front Endocrinol (Lausanne); 2019; 10():192. PubMed ID: 31024443
    [No Abstract]   [Full Text] [Related]  

  • 15. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.
    Perros P; Žarković M; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi A; Bournaud C; Brix TH; Covelli D; Ćirić S; Daumerie C; Eckstein A; Fichter N; Führer D; Hegedüs L; Kahaly GJ; Konuk O; Lareida J; Lazarus J; Leo M; Mathiopoulou L; Menconi F; Morris D; Okosieme O; Orgiazzi J; Pitz S; Salvi M; Vardanian-Vartin C; Wiersinga W; Bernard M; Clarke L; Currò N; Dayan C; Dickinson J; Knežević M; Lane C; Marcocci C; Marinò M; Möller L; Nardi M; Neoh C; Pearce S; von Arx G; Törüner FB
    Br J Ophthalmol; 2015 Nov; 99(11):1531-5. PubMed ID: 25953846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.
    Zang S; Ponto KA; Kahaly GJ
    J Clin Endocrinol Metab; 2011 Feb; 96(2):320-32. PubMed ID: 21239515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy of two different glucocorticoid regimens for treatment of active moderate-to-severe Graves' orbitopathy.
    Stoynova MA; Shinkov AD; Dimitrova ID; Yankova IA; Kovatcheva RD
    Int Ophthalmol; 2023 Dec; 43(12):4747-4757. PubMed ID: 37698660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.
    Perros P; Hegedüs L; Bartalena L; Marcocci C; Kahaly GJ; Baldeschi L; Salvi M; Lazarus JH; Eckstein A; Pitz S; Boboridis K; Anagnostis P; Ayvaz G; Boschi A; Brix TH; Currò N; Konuk O; Marinò M; Mitchell AL; Stankovic B; Törüner FB; von Arx G; Zarković M; Wiersinga WM
    Orphanet J Rare Dis; 2017 Apr; 12(1):72. PubMed ID: 28427469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves' ophthalmopathy.
    Ueda-Sakane Y; Kanamoto N; Fushimi Y; Tanaka-Mizuno S; Yasuno S; Miura M; Sone M; Yasoda A; Okada T; Togashi K; Nakao K; Inagaki N
    Endocr J; 2016 Aug; 63(8):703-14. PubMed ID: 27263854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
    Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
    Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.